复尔康注射液抗肝肿瘤的实验

Anti-liver Tumor Experiment of Fuerkang Injection

目的研究复尔康注射液对移植性小鼠肝癌的治疗作用,为开发新制剂提供药效依据。方法将肝癌H22S及A型瘤细胞分别接种于小鼠腋皮下及腹腔内,每只小鼠接种瘤细胞数量为2×106,次日随机分组,实验组分别静脉/腹腔注射复尔康注射液315、157.5、78.75mg/(kg·d),连续给药10d,分别计算肿瘤抑制率及小鼠生命延长率。结果复尔康注射液大中小剂量组对肝癌H22S型实体瘤的抑制率分别为49.36%、39.10%、21.50%;对肝癌H22A型腹水瘤小鼠的生命延长率分别为82.19%、65.18%、50.61%。重复2次,结果基本相似。结论复尔康注射液对移植性肝癌小鼠有明显的治疗作用。

Objective To study the therapeutic effects of Fuerkang Injection on transplanted hepatoma in mice,so as to provide the drug efficacy basis for development of new preparations. Methods The hepatoma H22 S and A type tumor cells were iniected to the axilla subcutaneous and intraperitoneal of mice. Each of mice was inoculated with 2 × 10^6 tumor cells, The mice were divided into groups randomly in the next day. Experimental group were intravenous or intraperitoneal iniected with Fuerkang Injection 315, 157. 5,78. 75 mg/（kg, d） respectively for 10 days. Tumor inhibitory rate and survival extending rate of mice were calculated respectively. Results The inhibitory rate of Fuerkang Injection at high dose,middle dose and low dose group to hepatoma H22 S type solid tumor were 49. 36% 39. 10 %,21.50% respectively. The mice survival extending rate to hepatoma H22 A type ascites tumor were 82. 19%,65.18%, 50. 61 %. The results of repeated experiment for 2 times were similar to that of the above. Conclusion Fuerkang Injection hase significant curative effect on transplanted hepatocellular carcinoma in mice.